FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Frequently asked questions
What sector does FibroGen, Inc (FGEN) operate in?
FibroGen, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is FibroGen, Inc (FGEN) current stock price?
As of the latest data, FibroGen, Inc stock price is $9.71, with a previous close of $9.02. FibroGen, Inc gained $0.69 in the last trading session, representing a 7.65% increase.
What is FibroGen, Inc (FGEN) current market capitalization?
FibroGen, Inc market cap is approximately 39.28 million.
What is FibroGen, Inc (FGEN) Earnings Per Share (EPS)?
The trailing EPS is -$12.85, and the forward EPS is -$11.95.
Does FibroGen, Inc (FGEN) pay dividends?
No. FibroGen, Inc does not pay a dividend.
What is FibroGen, Inc (FGEN) beta (volatility) score?
FibroGen, Inc has a beta of 0.773, indicating lower volatility than the overall market.